Small Cell Lung Cancer in Elderly Patients: A Review

Authors:
Taofeek K. Owonikoko From the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, and Emory Winship Cancer Institute, Atlanta, Georgia.

Search for other papers by Taofeek K. Owonikoko in
Current site
Google Scholar
PubMed Close
 MD, PhD
and
Suresh Ramalingam From the University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, and Emory Winship Cancer Institute, Atlanta, Georgia.

Search for other papers by Suresh Ramalingam in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 6: Issue 3
Online Publication Date:
Mar 2008
DOI:
https://doi.org/10.6004/jnccn.2008.0028
Full access

Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer cases. Approximately 40% of those cases are diagnosed in patients older than 70 years, and this proportion continues to rise in contrast to the continued decline in incidence of SCLC among the general population. The optimal strategy to manage limited-stage SCLC involves a combined modality approach with platinum-based chemotherapy and external-beam thoracic radiation therapy. For extensive-stage disease, platinum-based combination chemotherapy is a mainstay of therapy. Elderly patients present unique challenges in terms of drug metabolism and organ reserve, which impact the outcome of therapeutic interventions. However, limited data are available to guide management decisions for SCLC in elderly patients, and therefore this article discusses recommendations for treatment.

Correspondence: Suresh Ramalingam, MD, Emory Winship Cancer Institute, 1365 Clifton Road, Suite #C-5090, Atlanta, GA 30322. E-mail: Suresh.ramalingam@emory.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Govindan R, Page N, Morgensztern D et al.. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539–4544.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Owonikoko TK, Ragin CC, Belani CP et al.. Lung cancer in elderly patients: an analysis of the SEER database. J Clin Oncol 2007;25:5570–5577.

  • 3.

    Hutchins LF, Unger JM, Crowley JJ et al.. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061–2067.

  • 4.

    Jatoi A, Hillman S, Stella P et al.. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005;23:9113–9119.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006;36:216–220.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720–2726.

  • 7.

    McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004;56:163–184.

  • 8.

    Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001;31:139–148.

  • 9.

    Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest 1997;112:1474–1479.

  • 10.

    Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767–790.

  • 11.

    Gaspar LE, Gay EG, Crawford J et al.. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 2005;6:355–360.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Ettinger DS, Aisner J. Changing face of small-cell lung cancer: real and artifact. J Clin Oncol 2006;24:4526–4527.

  • 13.

    Evans WK, Shepherd FA, Feld R et al.. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471–1477.

  • 14.

    Sundstrom S, Bremnes RM, Kaasa S et al.. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665–4672.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Johnson BE, Bridges JD, Sobczeck M et al.. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996;14:806–813.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Gatzemeier U, Hossfeld DK, Neuhauss R et al.. Phase II and III studies with carboplatin in small cell lung cancer. Semin Oncol 1992;19(1 Suppl 2):28–36.

  • 17.

    Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level [review]. Oncol Rep 2003;10:1663–1682.

  • 18.

    Skarlos DV, Samantas E, Kosmidis P et al.. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601–607.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Okamoto H, Watanabe K, Nishiwaki Y et al.. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999;17:3540–3545.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Matsui K, Masuda N, Yana T et al.. Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 2001;40:603–606.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Murray N, Grafton C, Shah A et al.. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3323–3328.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Shibata K, Kasahara K, Nakatsumi Y et al.. Carboplatin and etoposide in the treatment of elderly small cell lung cancer (SCLC). Lung Cancer 1997;18:54a.

  • 23.

    Fukuda M, Soda H, Soejima Y et al.. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. Cancer Chemother Pharmacol 2006;58:601–606.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Goss GD, Vincent M, Germond C et al.. Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer. Am J Clin Oncol 1993;16:295–300.

  • 25.

    Michel G, Leyvraz S, Bauer J et al.. Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer. Ann Oncol 1994;5:369–370.

  • 26.

    Evans WK, Radwi A, Tomiak E et al.. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 1995;18:149–155.

  • 27.

    Matsui K, Masuda N, Fukuoka M et al.. Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. Br J Cancer 1998;77:1961–1965.

  • 28.

    Quoix E, Breton JL, Daniel C et al.. Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol 2001;12:957–962.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Larive S, Bombaron P, Riou R et al.. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer 2002;35:1–7.

  • 30.

    Okamoto H, Naoki K, Narita Y et al.. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer 2006;53:197–203.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 1998;82:836–841.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348:563–566.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Souhami RL, Spiro SG, Rudd RM et al.. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577–580.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Ardizzoni A, Favaretto A, Boni L et al.. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis—a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005;23:569–575.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Findlay MP, Griffin AM, Raghavan D et al.. Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur J Cancer 1991;27:1597–1601.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Shepherd FA, Amdemichael E, Evans WK et al.. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soc 1994;42:64–70.

  • 37.

    Pignon JP, Arriagada R, Ihde DC et al.. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618–1624.

  • 38.

    Arriagada R, Pignon JP, Ihde DC et al.. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994;14(1B):333–335.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890–895.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Faivre-Finn C, Lee LW, Lorigan P et al.. Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments. Clin Oncol (R Coll Radiol) 2005;17:591–598.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 2007;25:4137–4145.

  • 42.

    Turrisi AT III, Kim K, Blum R et al.. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–271.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Movsas B, Moughan J, Komaki R et al.. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 2003;21:4553–4559.

  • 44.

    Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J et al.. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 2007;33:461–473.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Yuen AR, Zou G, Turrisi AT et al.. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000;89:1953–1960.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Schild SE, Stella PJ, Brooks BJ et al.. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005;103:2349–2354.

  • 47.

    Schild SE, Bonner JA, Hillman S et al.. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). J Clin Oncol 2007;25:3124–3129.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Bogart JA, Herndon JE II, Lyss AP et al.. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004;59:460–468.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Johnson BE, Crawford J, Downey RJ et al.. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:602–622.

  • 50.

    Mascaux C, Paesmans M, Berghmans T et al.. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23–36.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000;83:8–15.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Bishop JF, Raghavan D, Stuart-Harris R et al.. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987;5:1574–1578.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Okamoto H, Watanabe K, Kunikane H et al.. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162–169.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Noda K, Nishiwaki Y, Kawahara M et al.. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85–91.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Hanna N, Bunn PA Jr, Langer C et al.. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038–2043.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Lara P, Redman M, Lenz H et al.. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): pharamacogenomic (PG) and comaparative toxicity analysis of JCOG 9511 and SWOG 0124 [abstract]. J Clin Oncol 2007;25(Suppl 1):390s. Abstract 7524.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Hermes A, Bergman B, Bremnes R et al.. A randomized phase III trial of rintecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study [abstract]. J Clin Oncol 2007;25(Suppl 1):390s. Abstract 7523.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Arriagada R, Pignon JP, Laplanche A, Le Chevalier T. Prophylactic cranial irradiation for small-cell lung cancer. Lancet 1997;349:138.

  • 59.

    Arriagada R, Le Chevalier T, Borie F et al.. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183–190.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Gregor A, Cull A, Stephens RJ et al.. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 1997;33:1752–1758.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Meert AP, Paesmans M, Berghmans T et al.. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001;1:5.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Auperin A, Arriagada R, Pignon JP et al.. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476–484.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database Syst Rev 2000:CD002805.

  • 64.

    Arriagada R, Le Chevalier T, Riviere A et al.. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505 randomized patients. Ann Oncol 2002;13:748–754.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Ludbrook JJ, Truong PT, MacNeil MV et al.. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys 2003;55:1321–1330.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Kotalik J, Yu E, Markman BR, Evans WK. Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;50:309–316.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995;12:231–235.

  • 68.

    Johnson BE, Becker B, Goff WB II et al.. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J Clin Oncol 1985;3:1659–1667.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Lee JS, Umsawasdi T, Lee YY et al.. Neurotoxicity in long-term survivors of small cell lung cancer. Int J Radiat Oncol Biol Phys 1986;12:313–321.

  • 70.

    Johnson BE, Patronas N, Hayes W et al.. Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer: further follow-up of 6- to 13-year survivors. J Clin Oncol 1990;8:48–56.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Ohonoshi T, Ueoka H, Kawahara S et al.. Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 1993;10:47–54.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Shaw EG, Su JQ, Eagan RT et al.. Prophylactic cranial irradiation in complete responders with small-cell lung cancer: analysis of the Mayo Clinic and North Central Cancer Treatment Group data bases. J Clin Oncol 1994;12:2327–2332.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Cull A, Gregor A, Hopwood P et al.. Neurological and cognitive impairment in long-term survivors of small cell lung cancer. Eur J Cancer 1994;30A:1067–1074.

  • 74.

    Wolfson AH, Bains Y, Lu J et al.. Twice-daily prophylactic cranial irradiation for patients with limited disease small-cell lung cancer with complete response to chemotherapy and consolidative radiotherapy: report of a single institutional phase II trial. Am J Clin Oncol 2001;24:290–295.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004;100:801–806.

  • 76.

    Postmus PE, Haaxma-Reiche H, Gregor A et al.. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998;46:29–32.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Postmus PE, Haaxma-Reiche H, Smit EF et al.. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000;18:3400–3408.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Seute T, Leffers P, Wilmink JT et al.. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006;24:2079–2083.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    van Oosterhout AG, van de Pol M, ten Velde GP, Twijnstra A. Neurologic disorders in 203 consecutive patients with small cell lung cancer. Results of a longitudinal study. Cancer 1996;77:1434–1441.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Souhami RL, Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990;61:584–589.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Slotman B, Faivre-Finn C, Kramer G et al.. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664–672.

  • 82.

    von Pawel J, Schiller JH, Shepherd FA et al.. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658–667.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Eckardt JR, von Pawel J, Pujol JL et al.. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086–2092.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    O'Brien ME, Ciuleanu TE, Tsekov H et al.. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441–5447.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Sandler A, Gray R, Perry MC et al.. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–2550.

  • 86.

    Arnold AM, Seymour L, Smylie M et al.. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007;25:4278–4284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Sandler A, Szwaric S, Dowlati A et al.. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol 2007;25(Suppl 1):400s. Abstract 7564.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Ready N, Dudek AZ, Wang XF et al.. CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) [abstract]. J Clin Oncol 2007;25(Suppl 1):400s. Abstract 7563.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89.

    Ramalingam SS, Dahlberg SE, Langer CJ et al.. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study [abstract]. J Clin Oncol 2007;25(Suppl 1):393s. Abstract 7535.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2008 by the National Comprehensive Cancer Network
Page Numbers:
12
Article Category:
Research Article
Received:
01 Oct 2007
Accepted:
09 Nov 2007
Print Publication Date:
01 Mar 2008
Online Publication Date:
Mar 2008
Keywords:
Elderly; small cell lung cancer; limited-stage; extensive-stage; PCI

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 650 413 17
PDF Downloads 329 101 9
EPUB Downloads 0 0 0